Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Oral capecitabine (Xeloda) is an effective drug with favourable safety in adjuvant and metastatic colorectal cancer. Oxaliplatin-based therapy is becoming standard for Dukes' C colon cancer in patients suitable for combination therapy, but is not yet approved by the UK National Institute for He...

Full description

Bibliographic Details
Main Authors:	Cassidy, J, Douillard, J, Twelves, C, McKendrick, J, Scheithauer, W, Bustová, I, Johnston, P, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K, Cowell, W, Garrison, L
Format:	Journal article
Language:	English
Published:	2006

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial.

Similar Items